GEOVAX LABS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
GEOVAX LABS, INC. (GOVX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 0.00% for the 12-month period ending 2025-12-31, per its S-1 filed 2026-09-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-09-17
- GEOVAX LABS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was 0.00%.
- GEOVAX LABS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was 0.00%, a 100.00% decline from fiscal 2021.
- GEOVAX LABS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was 0.20%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2025-12-31 | 0.00% S-1 · filed 2026-09-17 |
| 2024-12-31 | 0.00% S-1 · filed 2026-09-17 |
| 2023-12-31 | 0.00% 10-K · filed 2025-03-27 |
| 2022-12-31 | 0.00% 10-K · filed 2024-02-29 |
| 2021-12-31 | 0.20% 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B |